INTRODUCTION

In female dogs, mammary glands are frequent locations for the development of tumours and form second most common neoplasia (Maiti, 2006; Maiti et al., 2009; Khimta et al., 2010; Maiti et al., 2011; Dileepkumar et al., 2015). Activated genes present in different tumours are not normally expressed in the tissue from which they originate. The “tumour markers” are the proteins derived from the expression of these genes. For diagnosis and assessing the evolution of the tumours, detection and quantification of these proteins or tumour markers are so essential.

The p53 gene mutations and protein overexpression are useful predictors of increased malignant potential and poor prognosis in canine mammary tumours (Lee et al., 2004). The p53 is a significant prognostic marker for survival in early breast cancer in human (Linjawi et al., 2004). The p53 is the most commonly mutated gene in human cancers and is found to be altered in dog cancers. In canine mammary tumours, the p53 gene may be useful marker for evaluating malignancy in canine mammary tumours.
Human and canine mammary tumours are frequently similar to their biological properties and histological origin and many researchers suggest that canine mammary tumours may serve as good models for human breast tumours (Ilhan et al., 2008). The present study is therefore, designed to investigate the efficiency and expression of p53 and Cox-2 genes as tumour markers in different histological types of canine mammary tumours through RTqPCR technology.

MATERIALS AND METHODS

A total of 12 canine mammary tumours were collected during surgery or biopsy in the Institute Referral Veterinary Polyclinics (Figure 1A and 1B). Clinical staging of the canine mammary tumours was done as per previous report (Owen, 1980). Samples of 12 normal mammary tissues were obtained from 12 clinically healthy dogs without any tumours.

Tissue samples were first fixed in 10% formalin, and then it was stained with Haematoxylin and Eosin (H&E) for histopathological examination. Diagnosis of mammary tumours was made by two independent pathologists according to WHO classification system of canine mammary tumours (Misdorp et al., 1999).

Tumour mass was collected by biopsy/surgery. The total RNA was isolated from mammary tumours using Tri-Reagent following the manufacturer's instructions (Sigma, USA). The first strand cDNA was synthesized using iScript Select cDNA Synthesis Kit (BIORAD). Negative controls were run that contained all the components except reverse transcriptase. Real-Time PCR (Mode 7500) was used for quantification of the expression of mRNA of the candidate genes. Primer Express 3.0 software was used for designing gene specific primers for the genes on the basis of respective cDNA sequence given below in Table 1.

<table>
<thead>
<tr>
<th>Genes</th>
<th>Primer sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>p53</td>
<td>F: 5’-GCGGCCCATCCTCCTATACT-3’&lt;br&gt;R: 5’-CACAAACGGGTACCCTCAAGGC-3’</td>
</tr>
<tr>
<td>Cox-2</td>
<td>F: 5’-ATGGGGTGAGGCAAGGCAAGAA-3’&lt;br&gt;R: 5’-GGTGAAAGTGCTGGCCAAGAAT-3’</td>
</tr>
<tr>
<td>RPL</td>
<td>F: 5’-ACCAGTCATACCGATATGTCAAAA-3’&lt;br&gt;R: 5’-TTGTCAATGCCTCTGGGGTTTC-3’</td>
</tr>
</tbody>
</table>

For the analysis of data, Ribosomal protein (RPL) was used as a house-keeping gene. In all samples, PCR reactions were performed in triplicate. PCR amplification was done in 20μl volume reaction containing 1X SYBR Green PCR master mix, 5 pmols of each gene-specific primer and 3 μl of cDNA.
4.0 μl of cDNA template were used. PCR cycling conditions were carried out as described in the Table 2. For the real time PCR assay, negative and positive controls were included. The cDNA was not added in the negative control (NTC). For determination of the efficiency of the selected primer pairs, calculation was done as follows: a serial dilution of the template was run with each primer pair, plotted the log of the dilution against the Ct value of each dilution. To calculate the efficiency of the PCR reaction, the slope of the resulting regression equation was used using the equation:

\[ E = -1 + 10(-1/\text{slope}) \]

A dissociation curve was generated after completion of amplification for each sample and analyzed in comparison to negative and positive controls, to determine the specificity of PCR reaction. Relative Quantification (RQ) using the comparative CT method was used for calculation of mRNA expression of candidate genes (Livak and Schmittgen, 2011).

The comparative critical threshold (CT) value was utilized for evaluation of relative quantification of gene expression. The ΔCT value was calculated by subtracting CT values for each mature mRNA reaction from the respective CT values of the RPL control (i.e. Ct target gene - Ct endogenous control = ΔCt, Normalization to endogenous control). Normalization to calibrator sample was done by calculating ΔΔCt (ΔCt sample - ΔCt calibrator = ΔΔCt). Relative quantitative (RQ) = 2^-ΔΔCt and the graphical representation was made based on these data.

All the data were analyzed by analysis of variance (ANOVA) as per standard statistical methods, using SPSS software package (version 16). The various scores were compared with Kruskal-Wallis test.

Necessary permission was undertaken from the Institute Animal Ethics Committee (IAEC) to conduct this research work in clinical cases.

**RESULTS**

Canine mammary neoplasm cases were presented as circumscribed nodules with variable size. The 12 cases were recorded in the age group of 7-15 years. Out of 12 mammary tumours, five cases had multiple growths and seven cases had solitary growth. Ulcerated and infected were in four cases whereas eight cases were non-infected. Clinical staging of the 12 canine mammary tumours were recorded; 6 cases (50%) were in clinical stage IV, followed by 4 cases (33.33%) were in stage III and 1 case (8.33%) each in stage II and stage V.

The detailed histopathological findings in canine mammary tissues (normal and tumours) were shown in Table 3. Among the 12 mammary tumours investigated, 5 were considered as benign lesions and were essentially adenomas and benign mixed tumour. Carcinomas were the most frequent malignant tumours whereas malign mixed tumour also identified. The main types of carcinomas found in the present study were solid carcinomas and papillary adenocarcinoma (Figure 2A and 2B).

RNA samples that showed a smear with three higher intensity ribosomal RNA bands of about 28s, 18s and 5.8s RNA on 1% agarose gel electrophoresis were processed (Figure 3).

**Table 3: Histological type of mammary tumours**

<table>
<thead>
<tr>
<th>Histological diagnosis</th>
<th>No of samples</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Normal mammary gland</td>
<td>12</td>
</tr>
<tr>
<td>(2) Benign tumours</td>
<td></td>
</tr>
<tr>
<td>• Simple adenoma</td>
<td>02</td>
</tr>
<tr>
<td>• Complex adenoma</td>
<td>01</td>
</tr>
<tr>
<td>• Papillary adenoma</td>
<td>01</td>
</tr>
<tr>
<td>• Benign mixed tumour</td>
<td>01</td>
</tr>
<tr>
<td>(3) Malignant tumours</td>
<td></td>
</tr>
<tr>
<td>• Solid carcinoma</td>
<td>02</td>
</tr>
<tr>
<td>• Papillary adenocarcinoma</td>
<td>02</td>
</tr>
<tr>
<td>• Squamous cell carcinoma</td>
<td>01</td>
</tr>
<tr>
<td>• Fibrosarcoma</td>
<td>01</td>
</tr>
<tr>
<td>• Mixed tumour carcinoma</td>
<td>01</td>
</tr>
</tbody>
</table>

![Figure 2](image2.png)

**Figure 2:** a) Solid carcinoma characterized by pleomorphic cells with vesicular nucleus (H&E x40); b) Papillary adenocarcinoma characterized by pockets of proliferative cells invading the parenchyma in papillary pattern with numerous mitotic figures (H&E x10)

![Figure 3](image3.png)

**Figure 3:** Quality and integrity of total RNase isolated from canine mammary tumour
RNA samples with OD260/OD280 ranged at 1.96 – 2.02, indicating high quality RNA, were used for cDNA synthesis. RNA samples that showed only IGBP3 cDNA specific band of ~233 bp were used for RTqPCR for p53 gene (Figure 4).

Figure 4: PCR amplification of cDNA to check DNA contamination

Amplification curve of different genes are presented in Figure 5. The dissociation curves of various genes have been shown in the Figure 6. There were higher levels of the p53 expressions detected in 9 out of 12 (75 %) cases when compared with normal tissues. Mean p53 expression levels of tumour and normal mammary tissue were 4.7333 ± 1.4999 and 1.00 ± .00 respectively. Comparing the levels of expression of p53 in the canine mammary tumour and the normal mammary tissue, there was a significant increase (P<0.05) in expression of p53 in tumour tissue. Relative gene expression level of p53 gene has been shown graphically group wise and individually in Figure 7 and 8 respectively.

Higher level of Cox-2 expressions was detected in 10 out of 12 (83.33%) cases when compared with normal tissues. Mean Cox-2 expression levels of tumour and normal mammary tissue were 6.93 ± 2.71 and 1.00 ± .00 respectively. Comparing the levels of expression of Cox-2 in the canine mammary tumour and the normal mammary tissue, there was a significant increase (P<0.05) in expression of Cox-2 in tumour tissue. Relative gene expression level of
Cox-2 gene has been shown graphically group wise and individually in Figure 9 and 10 respectively.

**Figure 7**: Relative gene expression of p53 gene (Group-wise)

**Figure 8**: Relative gene expression of p53 gene (Individually) (NCMT-Normal canine mammary tissue; CMTT-canine mammary tumour tissue)

**Figure 9**: Relative gene expression of Cox-2 gene, (Group-wise)

**Figure 10**: Relative gene expression of Cox-2 gene (Individually) (NCMT-Normal canine mammary tissue; CMTT-canine mammary tumour tissue)

**DISCUSSION**

Mammary neoplasms are the second most frequently encountered neoplasm in female dogs after skin tumour (Divya et al., 2015). Several efforts have been made towards the evaluation of prognostic factors including oncogene or tumour markers expression.

Tumour markers may reflect the neoplastic process by a high/low level of expression relative to that of normal cells, offering a putative use in diagnosis of cancer. They can be measured quantitatively or qualitatively by chemical, immunological or molecular methods. Measurement of tumour markers levels, when used along with other diagnostic tests, can be useful in the detection and diagnosis of some type of cancers (Kumar and Pawaiya, 2010).

In this study, p53 expression was observed in 66.67 % of the mammary tumours as compared to normal tissue where expression was 33.33%. The results showed a high incidence of p53 overexpression in the canine mammary tumour and particularly this expression was more in malignant tumours than benign. The presence of a p53 mutation is significantly associated with larger tumour diameter (Faille et al., 1994). The p53 mutation used as a risk factor for increased risk of recurrence and death from breast cancer independent of tumour size, hormone receptor levels (Iacopetta et al., 1998). The results of the present study are in agreement with other researcher (Rungzipipat et al., 1999), who also observed p53 overexpression in different canine tumours. Determination of the p53 status in canine cancer patients helped in investigating the role of p53 in mammary tumour formation and its progression (Veldhoen et al., 1999). The p53 gene is an independent factor whose overexpression indicates worst prognosis in canine mammary tumours. In agreement with this study, overexpression of p53 gene was the useful predictors of increased malignant potential or malignancy of mammary tumours in female dogs (Lee et al., 2004; Ilhan et al., 2008).

In this study, high levels of Cox-2 expression were detected in 83.33 % of the mammary tumours, where as in normal tissue, expression was 16.66 %. The results showed a high incidence of Cox-2 overexpression in canine mammary
tumour and a trend to be associated with the advanced stages. Cox-2 overexpression was also reported in human and canine mammary tumour (Prescott and Fitzpatrick, 2002; Mohammad et al., 2004). Cox-2 expression is more frequent and more intense in malignant than in benign tumours (Dore et al., 2003). In canine mammary carcinomas, Cox-2 overexpression is directly associated with a high tumour histological grade, greater tumour metastatic and recurrence rates, and reduced survival time. Higher expression of this gene was related to the poor prognosis (Heller et al., 2005; Milanta et al., 2006). The result of the present study was in agreement with other workers who found that about 83% metastatic lesions of canine mammary gland neoplasia having Cox-2 expression and about 58% exhibit strong Cox-2 expression (Ilhan et al., 2008). For the treatment and control of advanced neoplastic mammary disease in female dogs, Cox-2 inhibitors could be an alternative (Lavalle et al., 2009).

ACKNOWLEDGEMENTS

The authors are highly thankful to the Director of the Institute, Head, Surgery Division and Incharge, Veterinary Referral Polyclinics for providing necessary facilities to carry out this study.

CONFLICT OF INTERESTS

The authors declare that there is no conflict of interests regarding the publication of this paper.

AUTHORS’ CONTRIBUTION

All authors contributed equally.

REFERENCES


June 2016 | Volume 4 | Issue 6 | Page 299


